TWI735413B - 抗藥性癌症之治療方法 - Google Patents

抗藥性癌症之治療方法 Download PDF

Info

Publication number
TWI735413B
TWI735413B TW104117852A TW104117852A TWI735413B TW I735413 B TWI735413 B TW I735413B TW 104117852 A TW104117852 A TW 104117852A TW 104117852 A TW104117852 A TW 104117852A TW I735413 B TWI735413 B TW I735413B
Authority
TW
Taiwan
Prior art keywords
properazin
cancer
cells
group
combination
Prior art date
Application number
TW104117852A
Other languages
English (en)
Chinese (zh)
Other versions
TW201617078A (zh
Inventor
黃奇英
張牧新
陳冠宇
吳駿翃
鄭大山
余晟豪
Original Assignee
國立陽明交通大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國立陽明交通大學 filed Critical 國立陽明交通大學
Publication of TW201617078A publication Critical patent/TW201617078A/zh
Application granted granted Critical
Publication of TWI735413B publication Critical patent/TWI735413B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW104117852A 2014-06-02 2015-06-02 抗藥性癌症之治療方法 TWI735413B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462006630P 2014-06-02 2014-06-02
US62/006,630 2014-06-02

Publications (2)

Publication Number Publication Date
TW201617078A TW201617078A (zh) 2016-05-16
TWI735413B true TWI735413B (zh) 2021-08-11

Family

ID=54766042

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104117852A TWI735413B (zh) 2014-06-02 2015-06-02 抗藥性癌症之治療方法

Country Status (10)

Country Link
US (1) US20170105999A1 (cg-RX-API-DMAC7.html)
EP (1) EP3148547B1 (cg-RX-API-DMAC7.html)
JP (1) JP2017516827A (cg-RX-API-DMAC7.html)
KR (1) KR102053507B1 (cg-RX-API-DMAC7.html)
CN (1) CN106794184A (cg-RX-API-DMAC7.html)
AU (2) AU2015271561A1 (cg-RX-API-DMAC7.html)
CA (1) CA2963269A1 (cg-RX-API-DMAC7.html)
TW (1) TWI735413B (cg-RX-API-DMAC7.html)
WO (1) WO2015184794A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201608820B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695138B1 (en) * 2016-10-17 2017-07-04 Acenda Pharma, Inc. Phenothiazine derivatives and methods of use thereof
WO2019204764A1 (en) * 2018-04-19 2019-10-24 Washington University Compositions and methods of use thereof for treatment of proteinopathies
CN110507653B (zh) * 2019-08-02 2022-12-02 北京赛而生物药业有限公司 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用
CN113264903A (zh) * 2021-05-27 2021-08-17 郑州大学 一种吩噻嗪类化合物及其制备方法和应用
TW202510889A (zh) * 2023-07-31 2025-03-16 國立陽明交通大學 透過影響癌細胞膜受體及源自其產生之胞外體治療癌症之組合物及方法
KR20250094197A (ko) 2023-12-18 2025-06-25 서울대학교산학협력단 신규 베타-카볼린 유도체 및 이를 포함하는 약물 내성 암 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185243C (zh) 1999-10-26 2005-01-19 中国人民解放军第二军医大学 一种防治心脑血管疾病的四羟基二苯乙烯苷类新化合物
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
BRPI0618473A2 (pt) * 2005-11-11 2011-08-30 Pfizer combinações e métodos de uso de um oligodeoxinucleotìdeo imunomodulador
EP2120900A2 (en) * 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer
EP2702054B1 (en) * 2011-04-29 2018-10-24 The Trustees of The University of Pennsylvania Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
CA2834566A1 (en) * 2011-05-18 2012-11-22 Merck Sharp & Dohme Corp. Therapeutic anti-igf1r combinations
WO2013070688A1 (en) * 2011-11-11 2013-05-16 Yale University Reprogramming urokinase into an antibody-recruiting anticancer agent
US8809299B2 (en) * 2012-03-28 2014-08-19 Mcmaster University Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
ZA201608820B (en) 2019-12-18
EP3148547A1 (en) 2017-04-05
AU2018222881A1 (en) 2018-09-13
US20170105999A1 (en) 2017-04-20
TW201617078A (zh) 2016-05-16
EP3148547C0 (en) 2024-01-03
EP3148547B1 (en) 2024-01-03
AU2015271561A1 (en) 2017-01-19
CN106794184A (zh) 2017-05-31
EP3148547A4 (en) 2018-01-10
WO2015184794A1 (en) 2015-12-10
KR102053507B1 (ko) 2019-12-06
KR20170040183A (ko) 2017-04-12
CA2963269A1 (en) 2015-12-10
JP2017516827A (ja) 2017-06-22

Similar Documents

Publication Publication Date Title
TWI735413B (zh) 抗藥性癌症之治療方法
ES2962890T3 (es) Uso del cannabidiol en el tratamiento del complejo de esclerosis tuberosa
ES2808781T3 (es) Combinaciones de moduladores duales de IRS/STAT3 y agentes anticancerígenos para el tratamiento del cáncer
ES2791539T3 (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresión de DUX4
JP2018131454A (ja) 新規癌治療法としてのアリール炭化水素受容体（ＡｈＲ）改変物質
BR112013028095B1 (pt) Uso de inibidores de csf-1r para o tratamento de tumores cerebrais
WO2013060305A1 (en) Pharmaceutical composition for elimination of cancer stem cells
JP2018533560A (ja) 癌を治療するための併用療法
TWI640311B (zh) 芳基喹啉衍生物作爲血管生成擬態抑制劑之新穎用途
JP2016522202A (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
US20210085649A1 (en) Methods and use of compounds that bind to rela of nf-kb
TW202038947A (zh) 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
CN104364232B (zh) 用于癌症治疗的激酶抑制剂
JP7349983B2 (ja) 障害治療用のトリプトニドまたはトリプトニド含有組成物
TW201628624A (zh) 使用啡噻嗪用於治療癌症的醫藥組成物
TW201709905A (zh) 治療癌症之方法
KR20200005573A (ko) 암의 치료를 위한 약제학적 조합물
TW202038960A (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
TW200902034A (en) Effective treatment of tumors and cancer with prodrugs of triciribine
KR20150083353A (ko) 경요도적 주입용 방광암 예방 또는 치료를 위한 약제학적 조성물
CN111655256A (zh) Adam9抑制剂及其用途
RU2415672C2 (ru) Производные пиримидиламинобензамида для лечения синдрома гиперэозинофилии
CN101282728A (zh) 有机化合物的组合
WO2014047398A1 (en) Modulation of asymmetric proliferation
KR20220036856A (ko) 혈액 순환 미세체외소체 매개 암 치료용 조성물

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees